Randomized control trials in ALS: lessons learned

References

• Olarte MR, Gersten JC, Zabriskie J, Rowland LP. Transfer factor is ineffective in amyotrophic lateral sclerosis. Ann Neurol 1979; 5(4): 385–388.
   PubMed Web of Science ®Google Scholar
• Bradley WG, Hedlund W, Cooper C et al. A double- blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology 1984; 34: 1079–1082.
   Google Scholar
• Brooke MH, Florence JM, Heller SL et al. Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology 1986; 36: 146–151.
   Google Scholar
• Mitsumoto H, Salgado ED, Negroski D et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 1986; 36: 152–159.
   Google Scholar
• Brooks BR, Sufit RL, Montgomery GK, Beaulieu DA, Erickson LM. Intravenous thyrotropin releasing hormone in patients with amyotrophic lateral sclerosis: dose response and randomized concurrent placebo controlled pilot studies. Neurol Clin 1987; 5: 143–158.
   PubMed Web of Science ®Google Scholar
• The National TRH Study Group. Multicenter controlled trial: no effect of alternate-day 5mg/kg subcutaneous thyrotropin- releasing hormone (TRH) on isometric strength decrease in amyotrophic lateral sclerosis [abstract]. Neurology 1989; 39 (suppl): 322.
   Google Scholar
• Appel SH, Stewart SS, Appel V et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 1988; 45(4): 381–386.
   Google Scholar
• Steiner TJ. Motor Neurone Disease: Experience with Large Multicenter Trials. In: Guiloff RJ, ed. Clinical Trials in Neurology. London: Springer-Verlag, 2001: 451–463.
   Google Scholar
• The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993; 43: 2466–2470.
   Google Scholar
• Tandan R, Bromberg MB, Forshew D et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data. Neurology 1996; 47: 1220–1226.
   Google Scholar
• Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993; 20: 297–301.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–591.
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Weverling GJ, Bossuyt P et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995; 52: 559–564.
   Google Scholar
• Miller RG, Shepherd R, Dao H et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 1996 6; 20: 101–104.
   Google Scholar
• Miller RG, Smith SA, Murphy JR et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 1996; 19: 511–551.
   Google Scholar
• The ALS CNTF Treatment Study (ACTS) Phase III Study Group. A double-blind placebo controlled trial of subcutaneous recom- binant human ciliary neurotrophic factor (rHCNTF) in amyo- trophic lateral sclerosis. Neurology 1996; 46: 1244–1249.
   PubMed Web of Science ®Google Scholar
• Miller RG, Petajan JH, Bryan WW et al. A placebo controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256–260.
   Google Scholar
• Lacomblez L, Bensimon G, Leigh PN et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–1431.
   Google Scholar
• Miller RG, Moore D, Young LA et al. Placebo controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1383–1388.
   Google Scholar
• Lai EC, Felice KJ, Festoff BW et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621–1630.
   Google Scholar
• Borasio GD, Robberecht W, Leigh PN et al. A placebo controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51: 583–586.
   Google Scholar
• Lange DJ, Murphy PL, Diamond B et al. Selegiline is ineffective in a collaborative double-blind controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998; 55: 93–96.
   Google Scholar
• BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS. The BDNF Study Group (Phase III). Neurology 1999; 52: 1427–1433.
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH Jr, Gelinas DF et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
   Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole- tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 9–18.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA et al. A randomized, placebo controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003; 61: 456–464.
   Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–445.
   Google Scholar
• Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998; 50: 62–66.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Tsuzaka K. Neurotrophic factors and neuro- muscular diseases. Part I and Part II. Muscle Nerve 1999; 22: 983–999 (I) and 1000–1021 (II).
   Google Scholar
• Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839–342.
   PubMed Web of Science ®Google Scholar
• Murray B, Mitsumoto H. Drug therapy in amyotrophic lateral sclerosis. In: Pourmand R, Harati Y, eds. Neuromuscular Disorders. New York: Lippincott, Williams and Wilkins. Advances in Neurology 2002; 88 63–82.
   Google Scholar
• Rowland LP, Schneider NA. Medical progress: amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–1700.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B et al. Riluzole and prognosis in ALS: findings of the Irish ALS registry from 1995–2000. ALS and other Motor Neuron Diseases 2001; 2 (suppl 2): 43–44.
   Google Scholar
• The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53: 141–147.
   Google Scholar
• Bryan WW, McIntire D, Camperlengo L et al. Factors influencing the use of riluzole by ALS patients. 8th International Symposium on ALS/MND. November1997(abstract).Published in J Neurol Sc.
   Google Scholar
• Cedarbaum JM, Stambler N. Disease status and use of ventilatory support by ALS patients. BDNF Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 19–22.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Davidson M, Moore DH et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotrophic Lateral Scler Other Motor Neuron Disord 2003; 4: 177–185.
   Google Scholar
• Munsat TL, Andres PL, Finison L, Conlon T, Thibodeaur L. The natural history of motor neuron loss in amyotrophic lateral sclerosis. Neurology 1988; 38: 409–413.
   PubMed Web of Science ®Google Scholar
• Munsat TL, Andres P, Skerry L. Therapeutic trials in amyotrophic lateral sclerosis: measurement of clinical deficit. In: Rose FC, ed. Amyotrophic Lateral Sclerosis. New York: Demos, 1990: 65–76.
   Google Scholar
• The World Federation of Neurology Research Group on Neuromuscular Diseases, Subcommittee on Motor Neuron Disease: Airlie House Guidelines. Therapeutic trials in amyo- trophic lateral sclerosis. J Neurol Sci 1995; 129 (suppl): 1–10.
   Google Scholar
• Kaufmann P, Lomen-Hoerth C. ALS treatment strikes out while trying for a homer: thetopiramate trial. Neurology 2003; 61: 434–435.
   PubMed Web of Science ®Google Scholar